Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the launch of novel polymerase and protease inhibitors have the potential to revolutionize the treatment of the hepatitis C virus (HCV). These novel agents include Idenix/Novartis's Valopicitabine, Vertex's VX-950, Schering-Plough's SCH-503034, and Gilead/Achillion's GS-9132.

According to an upcoming Pharmacor report entitled Hepatitis C Virus, the launch of HCV-specific anti-virals in novel drug classes such as the polymerase and protease inhibitors will improve upon the efficacy, safety, and convenience of current regimens. Furthermore, these novel HCV-specific anti- virals will launch at a time when the number of patients diagnosed with HCV is expected to expand significantly. The report also finds that major-market sales of HCV therapies will grow from $2 billion in 2004 to more than $10.5 billion in 2014.

"The protease inhibitors being developed by Idenix/Novartis, Vertex, Schering-Plough, and Gilead/Achillion are the most anticipated agents in this market and are likely to have a tremendous impact on HCV treatment regimens," said Aaron Woolsey, Ph.D., analyst at Decision Resources, Inc. "These novel drug launches, combined with the increasing number of patients being diagnosed with advanced liver disease and the re-treatment of patients who were un- responsive to initial therapy, will significantly expand the HCV market over the next ten years in the world's major pharmaceutical markets."

About Hepatitis C

Over 170 million people worldwide are infected with the hepatitis C virus and HCV is the leading cause of end-stage liver disease and hepatocellular carcinoma in the developed world.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Industry Pressures, Including a Recent Legal Ruling Against Pfizer, Will Affect the Statin Market in Germany

View Now